- Home
- BANL vs COEP Comparison
BANL vs COEP Comparison
Compare BANL & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANL | COEP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Malaysia | United States |
| Employees | N/A | 7 |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 72.7M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | BANL | COEP |
|---|---|---|
| Price | $0.68 | $10.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 31.9K |
| Earning Date | 04-15-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $6.32 |
| 52 Week High | $1.17 | $21.41 |
Technical Indicators
Market Signals| Indicator | BANL | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 67.25 | 36.57 |
| Support Level | $0.66 | $8.95 |
| Resistance Level | $0.77 | $13.23 |
| Average True Range (ATR) | 0.11 | 1.00 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 58.90 | 9.71 |
Price Performance
Historical ComparisonAbout BANL CBL International Limited
CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.